General Information of Drug (ID: DM5N4OA)

Drug Name
KVD824 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diabetic macular edema 9B71.02 Phase 2 [1]
Cross-matching ID
PubChem CID
139301832
TTD Drug ID
DM5N4OA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Plasma kallikrein (KLKB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ecallantide DMOF2C6 Retina venous occlusion 9B74.1 Approved [2]
Lanadelumab DMEH7YU Hereditary angioedema 4A00.14 Approved [3]
Berotralstat DMWA2DZ Hereditary angioedema 4A00.14 Approved [4]
KVD001 DMK4VOU Diabetic macular edema 9B71.02 Phase 2 [5]
THR-149 DMW8X05 Diabetic macular edema 9B71.02 Phase 2 [6]
(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone DM31OSD Discovery agent N.A. Investigative [7]
(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone DMT9FZD Discovery agent N.A. Investigative [7]
1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide DMG5MNZ Discovery agent N.A. Investigative [7]
D-Pro-Phe-Arg chloromethyl ketone DMRJQ8X Discovery agent N.A. Investigative [8]
(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone DMNVDLI Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasma kallikrein (KLKB1) TTMF8H9 KLKB1_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of KalVista Pharmaceuticals.
2 Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of Oxurion.
7 N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
8 Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.